Stress Fractures in Women: Symptoms, Causes, Drugs That Raise Risk, and How to Heal

What a Stress Fracture Actually Feels Like in Women

Pain that builds gradually during a run or walk, then lingers for hours after you stop. That is the most common story. Unlike a complete fracture, a stress fracture rarely announces itself with a single dramatic event. The discomfort starts mild and easy to dismiss, then worsens over days to weeks until weight-bearing becomes genuinely difficult.

The classic symptom pattern

The hallmark triad is:

• Localized, point-tender pain over a specific bone (pressing one finger directly on the area hurts sharply)
• Pain that worsens with activity and eases with rest in the early stages, though in later stages it may persist at rest
• Gradual onset over two to six weeks rather than a sudden snap

Women with a metatarsal stress fracture typically notice swelling across the top of the foot and pain when they stand on tiptoe. A tibial stress fracture produces a deep aching along the shin that is worse going down stairs. Femoral neck stress fractures, the most dangerous type, cause groin pain that may not feel obviously bone-related at all, which is one reason they are diagnosed late.

Why women feel these symptoms differently

Female athletes may attribute shin or foot pain to "normal training soreness," delaying care by an average of five to seven weeks after symptom onset. Hormonal fluctuations across the menstrual cycle also affect pain perception, meaning symptoms can seem variable rather than consistently progressive, further muddying the clinical picture.

Why Women Are at Higher Risk Than Men

Women account for approximately 1.5 to 3.5 times more stress fractures than men in comparable military and athletic populations, a gap that is not explained by training volume alone. The biology is specific and worth understanding because it changes what you do about it.

Estrogen and bone remodeling

Estrogen keeps osteoclast activity (bone breakdown) in check. When estrogen falls, whether because of exercise-induced amenorrhea, the perimenopause transition, or surgical menopause, resorption outpaces formation and bone mineral density (BMD) drops. The International Society for Clinical Densitometry notes that trabecular bone, the spongy inner structure dominant in the spine and femoral neck, is especially sensitive to estrogen withdrawal.

Women lose an average of 1 to 2% of bone mass per year in the first five years after menopause, with some women losing up to 3 to 5% annually. That rate of change is fast enough to convert previously safe training loads into fracture-producing ones.

The Female Athlete Triad and Relative Energy Deficiency in Sport

The Female Athlete Triad describes the interconnection of low energy availability, menstrual dysfunction, and low BMD. A 2014 consensus statement in the British Journal of Sports Medicine found that athletes with all three components had a stress fracture risk four to six times higher than athletes with none. The broader construct now recognized is Relative Energy Deficiency in Sport (RED-S), which applies across all genders but carries particular bone consequences for women because the link between energy deficit and estrogen suppression is direct and rapid.

Body composition and biomechanics

Women carry a higher proportion of body fat relative to lean mass and, on average, narrower bone cross-sections than men of similar height. Narrower bones have lower resistance to bending forces. The Q-angle (the angle between the quadriceps and the patellar tendon) is wider in women, altering load distribution at the knee and tibia. These are not flaws but anatomical realities that affect where fractures occur and how high the threshold needs to be before injury happens.

Drugs That Raise Your Stress Fracture Risk

Several commonly prescribed medications either lower bone density directly or impair the bone's ability to repair micro-damage. This section covers the drugs most relevant to women across different life stages.

Glucocorticoids (prednisone, dexamethasone, budesonide)

Oral glucocorticoids suppress osteoblast function and reduce calcium absorption from the gut. A 2017 analysis in the Journal of Bone and Mineral Research found that prednisone at doses as low as 2.5 mg per day for three months produced measurable BMD loss. Women with asthma, lupus, inflammatory bowel disease, or rheumatoid arthritis are disproportionately affected because these are conditions with higher female prevalence and often require long-term steroid use. If you take oral steroids for more than three months, ask your clinician specifically about bone protection.

Depot Medroxyprogesterone Acetate (DMPA, Depo-Provera)

DMPA suppresses ovarian estrogen production. A prospective study published in Contraception measured BMD losses of 5 to 7% over two years of DMPA use in premenopausal women. The FDA added a black-box warning noting that BMD loss may not be fully reversible. For adolescents and young women whose peak bone mass has not yet been reached (typically before age 25 to 30), this is especially relevant. If you are using DMPA and are also high-impact exercising at high volume, your stress fracture risk is compounded.

Aromatase Inhibitors (letrozole, anastrozole, exemestane)

Aromatase inhibitors (AIs) are standard adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. They block peripheral conversion of androgens to estrogen, driving estrogen to very low levels. The ATAC trial reported fracture rates of 11% in the anastrozole arm versus 7.7% in the tamoxifen arm over five years. Any woman starting an AI should have a baseline DEXA scan and a conversation about weight-bearing exercise, calcium, vitamin D, and potentially a bisphosphonate.

SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine)

Serotonin receptors are present on osteoblasts and osteoclasts, and serotonin signaling appears to suppress bone formation. A meta-analysis in Osteoporosis International found a 1.7-fold increased fracture risk associated with SSRI use, independent of fall risk. SSRIs are among the most prescribed medications in women of reproductive age and in the perimenopause. This does not mean you should stop your antidepressant, but it does mean bone health deserves monitoring if you are a long-term user and physically active.

Proton Pump Inhibitors (omeprazole, esomeprazole, pantoprazole)

Long-term PPI use reduces gastric acid, which is needed to ionize calcium for absorption. The FDA issued a safety communication in 2010 warning of possible increased fracture risk with prescription-dose PPI use for more than one year. Women already at elevated fracture risk (e.g., perimenopausal, low BMD, high training load) who require long-term PPIs should take calcium citrate rather than calcium carbonate, because citrate does not require acid for absorption.

Anticonvulsants (phenytoin, carbamazepine, valproate)

Enzyme-inducing anticonvulsants accelerate vitamin D catabolism via cytochrome P450 enzymes. Low vitamin D reduces intestinal calcium absorption and impairs bone mineralization. Women with epilepsy are already an underserved group in bone health monitoring. If you take any of these medications long-term, a serum 25-hydroxyvitamin D level and a DEXA scan are reasonable requests at any life stage.

Life-Stage Guide to Stress Fracture Risk

The following framework is original to WomanRx and synthesizes risk factors by hormonal life stage in a way that existing clinical summaries do not explicitly organize.

Reproductive years (teens through early 40s)

The biggest modifiable driver is energy availability. Undereating relative to training suppresses the hypothalamic-pituitary-ovarian axis within weeks, dropping estradiol and disrupting the menstrual cycle. A woman who has missed three or more consecutive periods in the context of exercise deserves a bone health assessment, not just reassurance that "it will come back."

Trying to conceive and early pregnancy

Stress fractures that occur during pregnancy are uncommon but documented, most often affecting the femoral neck and pubic rami as the pelvis accommodates the growing uterus. Load redistribution and relaxin-mediated ligamentous laxity change biomechanics substantially by the second trimester. Running volume should be guided by symptoms, not by a fixed mileage target.

Perimenopause (typically ages 45-55)

This is the phase with the steepest and most rapid bone loss. A woman who has been running marathons safely for 20 years may develop a metatarsal stress fracture in perimenopause at the same training volume that never caused problems before. ACOG Committee Opinion 655 and The Menopause Society's 2023 position statement on hormone therapy both acknowledge bone preservation as one of the established benefits of menopausal hormone therapy when started within ten years of menopause onset.

Postmenopause

Osteoporosis affects approximately one in two women over 50 in the United States. At this life stage, stress fractures can occur with activities most clinicians would consider gentle, such as brisk walking or low-impact aerobics. Atypical femoral fractures (AFF), a specific stress-fracture pattern at the subtrochanteric femur, are associated with very long-term bisphosphonate use, typically more than five to seven years. The absolute risk remains low but is specific enough to be worth discussing with your prescriber after five years on a bisphosphonate.

How Stress Fractures Are Diagnosed

X-rays miss up to 85% of stress fractures in the first two weeks after symptom onset. A normal X-ray does not rule out a stress fracture. MRI is the preferred first-line imaging for suspected stress fracture because it identifies bone marrow edema (the earliest signal of bony overload) and distinguishes low-risk from high-risk fracture patterns, which directly changes management.

Imaging options ranked by clinical utility

| Imaging | Sensitivity | Key limitation | |---|---|---| | MRI | ~99% | Cost, availability | | Bone scan (nuclear) | ~90% | Low specificity, radiation | | CT | Moderate | Poor for marrow edema | | X-ray | ~15-35% early | Misses most early fractures |

A DEXA scan for BMD is appropriate for any woman with a stress fracture who is under 50 without an obvious mechanical cause, any woman over 50, or any woman using one of the bone-depleting medications listed above.

The "hop test" and tuning fork test

A positive hop test (sharp localized pain when hopping on one foot) has reasonable sensitivity for tibial stress fractures in clinical studies, though not high enough to replace imaging. Some clinicians use a vibrating tuning fork applied to the suspected area; pain provocation suggests periosteal irritation. These are screening adjuncts, not diagnostic tools.

Drugs and Interventions Used to Treat or Prevent Stress Fractures

Managing a stress fracture involves two parallel goals: healing the current fracture and reducing the risk of the next one.

Load modification and orthopedic management

The cornerstone is controlled rest. Low-risk fractures (metatarsal shafts, fibula, proximal tibia) are managed with reduced weight-bearing, a stiff-soled shoe or boot, and a return-to-activity plan over six to eight weeks. High-risk fractures (femoral neck, navicular, anterior tibial cortex, sesamoids) may require non-weight-bearing crutches and, in some cases, surgical fixation. There is no drug that replaces this.

Vitamin D and calcium

A Cochrane review of vitamin D supplementation and fracture prevention found that vitamin D alone did not significantly reduce fracture risk, but vitamin D combined with calcium reduced hip fracture incidence by approximately 16% in older adults. The target serum 25-hydroxyvitamin D is 40 to 60 ng/mL for active women with low BMD. Most clinicians recommend 1,000 to 1,200 mg elemental calcium per day from food plus supplement combined, alongside 1,500 to 2,000 IU vitamin D3 daily for women with documented insufficiency.

Bisphosphonates (alendronate, risedronate, zoledronic acid)

Bisphosphonates are the first-line pharmacologic treatment for osteoporosis-related fracture risk in postmenopausal women. The FIT trial showed alendronate reduced vertebral fracture risk by 47% over three years in women with existing vertebral fractures. Zoledronic acid (5 mg IV once yearly) is an option for women who cannot tolerate oral bisphosphonates or have absorption concerns.

Bisphosphonates have a long skeletal half-life, approximately ten years. This is clinically important: a woman who stops alendronate before becoming pregnant should understand that drug residues remain in bone for years. The drug itself has been detected in fetal bone in animal studies, though human teratogenicity data are limited. See the pregnancy and lactation section below.

Teriparatide (Forteo) and abaloparatide (Tymlos)

These parathyroid hormone analogues are anabolic agents that stimulate new bone formation. A randomized trial published in NEJM showed teriparatide reduced vertebral fractures by 65% versus placebo in postmenopausal women with prior fractures. They are typically reserved for severe osteoporosis (T-score below negative 2.5 with existing fractures) because of cost, subcutaneous injection requirements, and a 24-month treatment cap. Neither is approved for stress fractures in athletes without osteoporosis, and evidence for that use remains thin.

Denosumab (Prolia)

Denosumab, a RANK-L inhibitor given as a subcutaneous injection every six months, reduces osteoclast activity. The FREEDOM trial showed a 68% reduction in vertebral fracture risk over three years compared to placebo. One important caveat for premenopausal women: denosumab is not approved for premenopausal women outside of cancer-related bone loss because its effects in that hormonal context are poorly characterized.

Hormonal strategies: Menopausal hormone therapy and combined oral contraceptives

For perimenopausal and postmenopausal women, menopausal hormone therapy (MHT) preserves BMD and has been shown in the Women's Health Initiative to reduce hip fracture risk by 34% compared to placebo. For younger women with exercise-induced hypothalamic amenorrhea, the American College of Sports Medicine recommends transdermal estradiol with cyclic progesterone over combined oral contraceptives because the pill suppresses IGF-1, which may blunt bone formation despite providing estrogen.

Pregnancy, Lactation, and Contraception Considerations

Pregnancy

Stress fractures during pregnancy most often affect the pubic rami and femoral neck. Imaging preference shifts to MRI (no ionizing radiation) over bone scan or CT. Weight-bearing restriction is safe in pregnancy and is the primary management strategy. Calcium needs increase to 1,000 mg per day in pregnant women under 19 and 1,300 mg in adolescents.

Bisphosphonates are not recommended during pregnancy. Animal data show fetal skeletal abnormalities at high doses, and bisphosphonates cross the placenta. FDA pregnancy category D evidence applies. Women of reproductive age who require bisphosphonate therapy should use effective contraception during treatment and discuss the long skeletal half-life with their prescriber before attempting conception.

Denosumab is also contraindicated in pregnancy. Women on denosumab should use contraception throughout treatment and for at least five months after the last dose.

Teriparatide and abaloparatide carry insufficient human data for use in pregnancy and should be discontinued before conception is attempted.

Lactation

Breastfeeding itself causes transient BMD loss of 3 to 5% at the lumbar spine over three to six months, mediated by PTHrP-driven calcium mobilization. This loss is largely reversible after weaning in most women. It does not require pharmacologic intervention in healthy women. However, postpartum women who are also high-volume exercising while breastfeeding are stacking three bone-depleting exposures (lactation, energy deficit, mechanical load), and that combination deserves clinical attention.

Bisphosphonates are present in animal breast milk and are not recommended during lactation. Calcium and vitamin D supplementation is appropriate and safe in lactation.

Contraception and bone health

The choice of contraception affects bone. DMPA (Depo-Provera) reduces BMD, as covered above. Combined oral contraceptives have a mixed record in adolescents: they may provide a small degree of bone protection via estrogen but suppress IGF-1 and may blunt peak bone mass accrual. Copper IUDs and hormonal IUDs (levonorgestrel, which has limited systemic absorption) have no meaningful effect on BMD and are preferred for women who need contraception without bone consequences.

Who This Is Right for and Who Needs a Different Approach

Most likely to benefit from standard rest-and-rehabilitate management

• Active women aged 20 to 45 with a single metatarsal or fibular stress fracture and regular menses
• Women with a clear mechanical cause (sudden training increase, poor footwear, hard surface)
• Women with normal or mildly reduced BMD (T-score above negative 1.5)

Needs deeper investigation and possible pharmacologic treatment

• Any woman with a second or third stress fracture within 12 months
• Women with amenorrhea (three or more missed periods) in the context of exercise
• Women aged 45 and older with a stress fracture and no DEXA in the past two years
• Women taking glucocorticoids, DMPA, aromatase inhibitors, or long-term SSRIs
• Women with a femoral neck stress fracture at any age (high-risk fracture; orthopedic referral is standard)
• Postmenopausal women with a stress fracture even from low-impact activity

Approach with caution

• Women who are pregnant with a suspected femoral neck or pelvic stress fracture: orthopedic consultation is warranted; surgical fixation may be necessary in some cases to protect the fetus from prolonged non-weight-bearing risk of DVT
• Women on bisphosphonates for more than five years who develop thigh pain: rule out atypical femoral fracture before treating as a standard overuse injury

Nutrition, Training Modification, and What Actually Helps

A 2021 systematic review in the British Journal of Sports Medicine confirmed that dietary calcium intake below 800 mg per day and serum 25-hydroxyvitamin D below 20 ng/mL independently predict stress fracture recurrence in female athletes. Getting both of those targets right before returning to full training is more predictive of outcomes than imaging resolution alone.

Return to running should follow a graduated protocol over at minimum four to six weeks after pain resolution, not after imaging resolution, because bone marrow edema on MRI can persist for months after the fracture has mechanically healed. A 2019 ACSM consensus statement recommends a staged return: pool running and cycling first, then walk-run intervals, then continuous running, with each stage lasting at least one week without pain before advancing.

Gait retraining to increase cadence (steps per minute) by 5 to 10% reduces tibial stress by approximately 6% per stride. This is a specific, measurable target your physiotherapist can work toward with you using a metronome or music at the target tempo.